Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / XBI - Provention Bio: Upgrading To A Strong-Buy Potential Cure For Type 1 Diabetes

XBI - Provention Bio: Upgrading To A Strong-Buy Potential Cure For Type 1 Diabetes

SPDR Series Trust S&P Biotech
  • We like the risk-reward of Provention Bio at this point and upgrading the rating to strong-buy from a buy. We accumulated a small option-sized position last week to play.
  • The company announced its intention to re-submit the BLA for Teplizumab targeting type 1 diabetes in at-risk individuals.
  • Approval of Teplizumab would represent a peak sales of USD 800-1.2B, and we view the probability of success to be around 80% at this point.
  • Based on our valuation, the company is ~80% undervalued from its risk-adjusted valuation, and even after the recent 50% rally, there is more room to rally.

For further details see:

Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Stock Information
Company Name: SPDR Series Trust S&P Biotech
Stock Symbol: XBI
Market: NYSE
Menu
XBI XBI Quote XBI Short XBI News XBI Articles XBI Message Board
Get XBI Alerts

News, Short Squeeze, Breakout and More Instantly...